# A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.

> **NCT07543224** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Reistone Biopharma Company Limited** · enrollment: 600 (estimated)

## Conditions studied

- Plaque Psoriasis Subjects

## Interventions

- **DRUG:** RSS0393 ointment 0.03%
- **DRUG:** RSS0393 ointment placebo

## Key facts

- **NCT ID:** NCT07543224
- **Lead sponsor:** Reistone Biopharma Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-01
- **Final completion:** 2027-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07543224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07543224, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07543224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*